On the morning of November 7th, 2022, Shenzhen Bay Laboratory and Shanghai Biotecan Pharmaceuticals Co., Ltd. (hereinafter referred to as “Biotecan”) signed a cooperation agreement to carry out in-depth cooperation in the fields of cutting-edge technology research and development, scientific and technological achievement transformation and industrial incubation. Both parties will fully integrate their respective resources and advantages, be based in Shenzhen, serve the Bay Area and face the world with the goal of “pilot demonstration zone”, provide strategic support for the development of the international frontier Medical Technology Pilot Zone, the Guangdong-Hong Kong-Macao Greater Bay Area Bio-pharmaceutical Industry Innovation Cooperation Zone and the future Life Science Center facing the world. Li Zigang, Executive Director of Pingshan Translational Medicine Center, and Ye Qingcai, CEO of Biotecan signed the strategic cooperation agreement on behalf of both sides. Hu Xiaojun, Party Secretary of Shenzhen Bay Laboratory, Lou Jingwei, Chairman of Biotecan and other leaders attended and witnessed the signing ceremony.
The Shenzhen Bay Laboratory is a major strategic deployment of Shenzhen, Guangdong province to build Guangdong-Hong Kong-Macao International Science and Technology Innovation Center and Comprehensive National Science Center. It is also a major innovation carrier fully supported by Shenzhen to build a pilot demonstration zone of socialism with Chinese characteristics.
As a leading enterprise in clinical molecular diagnosis and precision medicine in China, Biotecan has built a leading laboratory network in China, a biological sample database for major diseases in the Asia-Pacific population and a medical big data innovation platform; it has accumulated rich experience in the transformation and industrialization of cutting-edge life science and technology achievements.
The two parties will pool high-end technological innovation resources from the Guangdong-Hong Kong-Macao, the Yangtze River Delta and the international community, and international cutting-edge medical technology and medical products, be industrialization-oriented, integrate technical, clinical, industrial and other resources to create a model of industry-university-research collaborative innovation in the international digital medical field to promote technological research and development, industrial transformation and demonstration application in the fields of cutting-edge diagnostics, medical big data and innovative treatment, making positive contributions to the development of life and health industry in Shenzhen and the Guangdong-Hong Kong-Macao Greater Bay Area.
